Enterprise Value to EBITDA (EV/EBITDA)
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Allergan PLC, EBITDA calculation
US$ in thousands
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
| Item | Description | The company |
|---|---|---|
| EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Allergan PLC EBITDA increased from 2017 to 2018 and from 2018 to 2019. |
Enterprise Value to EBITDA Ratio, Current
Allergan PLC, current EV/EBITDA calculation, comparison to benchmarks
| Selected Financial Data (US$ in thousands) | |
| Enterprise value (EV) | 80,406,121) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 1,725,400) |
| Valuation Ratio | |
| EV/EBITDA | 46.60 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| AbbVie Inc. | 19.98 |
| Amgen Inc. | 14.08 |
| Bristol-Myers Squibb Co. | 7.48 |
| Danaher Corp. | 24.13 |
| Eli Lilly & Co. | 86.09 |
| Gilead Sciences Inc. | 12.20 |
| Johnson & Johnson | 16.08 |
| Merck & Co. Inc. | 39.74 |
| Moderna Inc. | — |
| Pfizer Inc. | 21.01 |
| Regeneron Pharmaceuticals Inc. | 15.67 |
| Thermo Fisher Scientific Inc. | 20.24 |
| EV/EBITDA, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 22.03 |
| EV/EBITDA, Industry | |
| Health Care | 20.48 |
Based on: 10-K (reporting date: 2019-12-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Allergan PLC, historical EV/EBITDA calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Enterprise value (EV)1 | 81,899,299) | 68,163,995) | 82,757,462) | 106,734,788) | 164,192,969) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 1,725,400) | 802,900) | (1,922,200) | 5,094,600) | 2,758,400) | |
| Valuation Ratio | ||||||
| EV/EBITDA3 | 47.47 | 84.90 | — | 20.95 | 59.52 | |
| Benchmarks | ||||||
| EV/EBITDA, Competitors4 | ||||||
| AbbVie Inc. | 13.68 | — | — | — | — | |
| Amgen Inc. | 12.26 | — | — | — | — | |
| Bristol-Myers Squibb Co. | 23.84 | — | — | — | — | |
| Danaher Corp. | 25.23 | — | — | — | — | |
| Eli Lilly & Co. | 21.40 | — | — | — | — | |
| Gilead Sciences Inc. | 11.77 | — | — | — | — | |
| Johnson & Johnson | 16.28 | — | — | — | — | |
| Merck & Co. Inc. | 13.66 | — | — | — | — | |
| Moderna Inc. | — | — | — | — | — | |
| Pfizer Inc. | 9.17 | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 14.80 | — | — | — | — | |
| Thermo Fisher Scientific Inc. | 19.74 | — | — | — | — | |
| EV/EBITDA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 14.94 | — | — | — | — | |
| EV/EBITDA, Industry | ||||||
| Health Care | 14.16 | — | — | — | — | |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
3 2019 Calculation
EV/EBITDA = EV ÷ EBITDA
= 81,899,299 ÷ 1,725,400 = 47.47
4 Click competitor name to see calculations.